Presentation Overview

The slide covers comprehensive content on <p><strong>Human fungal infections have increased dramatically in recent years, owing mainly to advances in surgery, cancer treatment, and critical care accompanied by&nbsp;increases in the use of broad-spectrum antimicrobials and the HIV epidemic. </strong></p> <p>&nbsp;<strong>Fungal infections are usually more difficult to treat than bacterial infections, because fungal organisms grow slowly and because fungal infections often occur in&nbsp;tissues that are poorly penetrated by antimicrobial agents (e.g., </strong><strong>devitalized or avascular tissues). Therapy of fungal infections usually requires prolonged treatment.</strong></p> <p><strong><em>Superficial fungal infections</em></strong> involve cutaneous surfaces (skin, nails, and hair), and mucous membrane surfaces (oropharynx and vagina).</p> <p><strong><em>Deep</em></strong><strong><em>seated</em></strong><strong><em> or disseminated fungal infections</em></strong> caused by dimorphic fungi, the yeasts Cryptococcus neoformans, and various Candida spp. respond to a limited number of systemic agents: amphotericin B (a polyene), flucytosine (a pyrimidine antimetabolite), the newer azoles (ketoconazole, fluconazole, itraconazole, and voriconazole), and caspofungin (an echinocandin).</p> . You can play the slide in our in-built slide player or download for offline reading.